Please Wait...

Loyal to the Pledge

Denmark, Norway Suspend AstraZeneca Vaccine over Blood Clot Fears

Denmark, Norway Suspend AstraZeneca Vaccine over Blood Clot Fears
folder_openEurope... access_time4 years ago
starAdd to favorites

By Staff, Agencies

Denmark will not use AstraZeneca’s COVID-19 vaccine for two weeks after reports that some recipients had developed serious blood clots, and in one case may have died as a result, the country’s authorities said on Thursday.

They did not say how many reports of blood clots there had been, but Austria has stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.

Danish health authorities said the country’s decision to suspend the shots for 14 days came after a 60-year-old woman in Denmark, who was given an AstraZeneca shot from the same batch that was used in Austria, formed a blood clot and died.

Danish authorities said they had responded “to reports of possible serious side effects, both from Denmark and other European countries”.

“It is currently not possible to conclude whether there is a link. We are acting early, it needs to be thoroughly investigated,” Health Minister Magnus Heunicke said on Twitter.

Following Denmark’s move, Norway announced later on Thursday that it was also halting the use of the AstraZeneca vaccine.

“This is a cautionary decision,” Geir Bukholm, director of infection prevention and control at the Norwegian Institute of Public Health [FHI], told a news conference.

FHI did not say how long the suspension would last.

“We … await information to see if there is a link between the vaccination and this case with a blood clot,” Bukholm said.

Also on Thursday, Italy said it would suspend use of an AstraZeneca batch that was different to the one used in Austria.

AstraZeneca meanwhile told Reuters news agency in a written statement the safety of its vaccine had been extensively studied in human trials, and peer-reviewed data had confirmed the vaccine was generally well tolerated.

The drug-maker said earlier this week its shots were subject to strict and rigorous quality controls and that there had been “no confirmed serious adverse events associated with the vaccine”. It also said it was in contact with Austrian authorities and would fully support their investigation.

Comments